远大赛威信生命科学

Grand Sevaxin Life Sciences is a clinical-stage biotechnology company specializing in the research and development of innovative therapeutic vaccines. Headquartered in Nanjing, China, the company operates as a key subsidiary of Grand Pharmaceutical Group following its acquisition in 2021. Grand Sevaxin leverages its proprietary DNA vaccine and recombinant protein platforms to address chronic infectious diseases and oncology, with a primary focus on achieving a functional cure for Chronic Hepatitis B. Its lead asset, GS-001, is a therapeutic DNA vaccine currently undergoing Phase 2 clinical evaluation in China. The company's pipeline also includes GS-002, a therapeutic vaccine targeting HPV-related infections. By integrating advanced delivery technologies like electroporation, Grand Sevaxin aims to provide potent immunotherapy solutions for high-unmet-need conditions.